Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome.

In the 50 years since acute respiratory distress syndrome (ARDS) was first described, substantial progress has been made in identifying the risk factors for and the pathogenic contributors to the syndrome and in characterising the protein expression patterns in plasma and bronchoalveolar lavage fluid from patients with ARDS. Despite this effort, however, pharmacological options for ARDS remain scarce. Frequently cited reasons for this absence of specific drug therapies include the heterogeneity of patients with ARDS, the potential for a differential response to drugs, and the possibility that the wrong targets have been studied. Advances in applied biomolecular technology and bioinformatics have enabled breakthroughs for other complex traits, such as cardiovascular disease or asthma, particularly when a precision medicine paradigm, wherein a biomarker or gene expression pattern indicates a patient's likelihood of responding to a treatment, has been pursued. In this Review, we consider the biological and analytical techniques that could facilitate a precision medicine approach for ARDS

Bioinformatic-driven search for metabolic biomarkers in disease

The search and validation of novel disease biomarkers requires the complementary power of professional study planning and execution, modern profiling technologies and related bioinformatics tools for data analysis and interpretation. Biomarkers have considerable impact on the care of patients and are urgently needed for advancing diagnostics, prognostics and treatment of disease. This survey article highlights emerging bioinformatics methods for biomarker discovery in clinical metabolomics, focusing on the problem of data preprocessing and consolidation, the data-driven search, verification, prioritization and biological interpretation of putative metabolic candidate biomarkers in disease. In particular, data mining tools suitable for the application to omic data gathered from most frequently-used type of experimental designs, such as case-control or longitudinal biomarker cohort studies, are reviewed and case examples of selected discovery steps are delineated in more detail. This review demonstrates that clinical bioinformatics has evolved into an essential element of biomarker discovery, translating new innovations and successes in profiling technologies and bioinformatics to clinical application

Sugar Alcohols Have a Key Role in Pathogenesis of Chronic Liver Disease and Hepatocellular Carcinoma in Whole Blood and Liver Tissues.

The major risk factors for hepatocellular carcinoma (HCC) are hepatitis C and B viral infections that proceed to Chronic Liver Disease (CLD). Yet, the early diagnosis and treatment of HCC are challenging because the pathogenesis of HCC is not fully defined. To better understand the onset and development of HCC, untargeted GC-TOF MS metabolomics data were acquired from resected human HCC tissues and their paired non-tumor hepatic tissues (n = 46). Blood samples of the same HCC subjects (n = 23) were compared to CLD (n = 15) and healthy control (n = 15) blood samples. The participants were recruited from the National Liver Institute in Egypt. The GC-TOF MS data yielded 194 structurally annotated compounds. The most strikingly significant alteration was found for the class of sugar alcohols that were up-regulated in blood of HCC patients compared to CLD subjects (p < 2.4 × 10-12) and CLD compared to healthy controls (p = 4.1 × 10-7). In HCC tissues, sugar alcohols were the most significant (p < 1 × 10-6) class differentiating resected HCC tissues from non-malignant hepatic tissues for all HCC patients. Alteration of sugar alcohol levels in liver tissues also defined early-stage HCC from their paired non-malignant hepatic tissues (p = 2.7 × 10-6). In blood, sugar alcohols differentiated HCC from CLD subjects with an ROC-curve of 0.875 compared to 0.685 for the classic HCC biomarker alpha-fetoprotein. Blood sugar alcohol levels steadily increased from healthy controls to CLD to early stages of HCC and finally, to late-stage HCC patients. The increase in sugar alcohol levels indicates a role of aldo-keto reductases in the pathogenesis of HCC, possibly opening novel diagnostic and therapeutic options after in-depth validation

Integrative Analysis To Select Cancer Candidate Biomarkers To Targeted Validation

Targeted proteomics has flourished as the method of choice for prospecting for and validating potential candidate biomarkers in many diseases. However, challenges still remain due to the lack of standardized routines that can prioritize a limited number of proteins to be further validated in human samples. To help researchers identify candidate biomarkers that best characterize their samples under study, a well-designed integrative analysis pipeline, comprising MS-based discovery, feature selection methods, clustering techniques, bioinformatic analyses and targeted approaches was performed using discovery-based proteomic data from the secretomes of three classes of human cell lines (carcinoma, melanoma and non-cancerous). Three feature selection algorithms, namely, Beta-binomial, Nearest Shrunken Centroids (NSC), and Support Vector Machine-Recursive Features Elimination (SVM-RFE), indicated a panel of 137 candidate biomarkers for carcinoma and 271 for melanoma, which were differentially abundant between the tumor classes. We further tested the strength of the pipeline in selecting candidate biomarkers by immunoblotting, human tissue microarrays, label-free targeted MS and functional experiments. In conclusion, the proposed integrative analysis was able to pre-qualify and prioritize candidate biomarkers from discovery-based proteomics to targeted MS.6414363543652Kulasingam, V., Diamandis, E.P., Strategies for discovering novel cancer biomarkers through utilization of emerging technologies (2008) Nature clinical practice Oncology, 5, pp. 588-599Wu, C.C., Hsu, C.W., Chen, C.D., Yu, C.J., Chang, K.P., Tai, D.I., Liu, H.P., Yu, J.S., Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas (2010) Molecular & cellular proteomics: MCP, 9, pp. 1100-1117Chen, R., Pan, S., Brentnall, T.A., Aebersold, R., Proteomic profiling of pancreatic cancer for biomarker discovery (2005) Molecular & cellular proteomics: MCP, 4, pp. 523-533Shimwell, N.J., Bryan, R.T., Wei, W., James, N.D., Cheng, K.K., Zeegers, M.P., Johnson, P.J., Ward, D.G., Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma (2013) British journal of cancer, 108, pp. 1854-1861White, N.M., Masui, O., Desouza, L.V., Krakovska, O., Metias, S., Romaschin, A.D., Honey, R.J., Siu, K.W., Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma (2014) Oncotarget, 5, pp. 506-518Rifai, N., Gillette, M.A., Carr, S.A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility (2006) Nature biotechnology, 24, pp. 971-983Whiteaker, J.R., Lin, C., Kennedy, J., Hou, L., Trute, M., Sokal, I., Yan, P., Gafken, P.R., A targeted proteomics-based pipeline for verification of biomarkers in plasma (2011) Nature biotechnology, 29, pp. 625-634Makawita, S., Diamandis, E.P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification (2010) Clinical chemistry, 56, pp. 212-222Picotti, P., Rinner, O., Stallmach, R., Dautel, F., Farrah, T., Domon, B., Wenschuh, H., Aebersold, R., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes (2010) Nature methods, 7, pp. 43-46Picotti, P., Bodenmiller, B., Aebersold, R., Proteomics meets the scientific method (2013) Nature methods, 10, pp. 24-27Gillette, M.A., Carr, S.A., Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry (2013) Nature methods, 10, pp. 28-34Chang, K.P., Yu, J.S., Chien, K.Y., Lee, C.W., Liang, Y., Liao, C.T., Yen, T.C., Chi, L.M., Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology (2011) Journal of proteome research, 10, pp. 4935-4947de Jong, E.P., Xie, H., Onsongo, G., Stone, M.D., Chen, X.B., Kooren, J.A., Refsland, E.W., Carlis, J.V., Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions (2010) PloS one, 5Hu, S., Arellano, M., Boontheung, P., Wang, J., Zhou, H., Jiang, J., Elashoff, D., Wong, D.T., Salivary proteomics for oral cancer biomarker discovery (2008) Clinical cancer research: an official journal of the American Association for Cancer Research, 14, pp. 6246-6252Sepiashvili, L., Hui, A., Ignatchenko, V., Shi, W., Su, S., Xu, W., Huang, S.H., Kislinger, T., Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy (2012) Molecular & cellular proteomics: MCP, 11, pp. 1404-1415van der Post, S., Hansson, G.C., Membrane Protein Profiling of Human Colon Reveals Distinct Regional Differences (2014) Molecular & cellular proteomics: MCPSimabuco, F.M., Kawahara, R., Yokoo, S., Granato, D.C., Miguel, L., Agostini, M., Aragao, A.Z., Paes Leme, A.F., ADAM17 mediates OSCC development in an orthotopic murine model (2014) Molecular cancer, 13, p. 24Liu, N.Q., Braakman, R.B., Stingl, C., Luider, T.M., Martens, J.W., Foekens, J.A., Umar, A., Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue (2012) Journal of mammary gland biology and neoplasia, 17, pp. 155-164Granato, D.C., Zanetti, M.R., Kawahara, R., Yokoo, S., Domingues, R.R., Aragao, A.Z., Agostini, M., Silva, A.R., Integrated proteomics identified up-regulated focal adhesion-mediated proteins in human squamous cell carcinoma in an orthotopic murine model (2014) PloS one, 9Kulasingam, V., Diamandis, E.P., Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets (2007) Molecular & cellular proteomics: MCP, 6, pp. 1997-2011Pham, T.V., Piersma, S.R., Warmoes, M., Jimenez, C.R., On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics (2010) Bioinformatics, 26, pp. 363-369Christin, C., Hoefsloot, H.C., Smilde, A.K., Hoekman, B., Suits, F., Bischoff, R., Horvatovich, P., A critical assessment of feature selection methods for biomarker discovery in clinical proteomics (2013) Molecular & cellular proteomics: MCP, 12, pp. 263-276Kim, Y., Ignatchenko, V., Yao, C.Q., Kalatskaya, I., Nyalwidhe, J.O., Lance, R.S., Gramolini, A.O., Drake, R.R., Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organconfined versus extracapsular prostate cancer (2012) Molecular & cellular proteomics: MCP, 11, pp. 1870-1884Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Mills, S.A., Parsa, A.T., Cancer and the complement cascade (2010) Molecular cancer research: MCR, 8, pp. 1453-1465Cho, M.S., Vasquez, H.G., Rupaimoole, R., Pradeep, S., Wu, S., Zand, B., Han, H.D., Dalton, H.J., Autocrine effects of tumor-derived complement (2014) Cell reports, 6, pp. 1085-1095Bensimon, A., Heck, A.J., Aebersold, R., Mass spectrometrybased proteomics and network biology (2012) Annual review of biochemistry, 81, pp. 379-405Bonne, N.J., Wong, D.T., Salivary biomarker development using genomic, proteomic and metabolomic approaches (2012) Genome medicine, 4, p. 82Leemans, C.R., Braakhuis, B.J., Brakenhoff, R.H., The molecular biology of head and neck cancer (2011) Nature reviews Cancer, 11, pp. 9-22Argiris, A., Karamouzis, M.V., Raben, D., Ferris, R.L., Head and neck cancer (2008) Lancet, 371, pp. 1695-1709da Silva, S.D., Ferlito, A., Takes, R.P., Brakenhoff, R.H., Valentin, M.D., Woolgar, J.A., Bradford, C.R., Kowalski, L.P., Advances and applications of oral cancer basic research (2011) Oral oncology, 47, pp. 783-791Macor, P., Tedesco, F., Complement as effector system in cancer immunotherapy (2007) Immunology letters, 111, pp. 6-13Bjorge, L., Hakulinen, J., Vintermyr, O.K., Jarva, H., Jensen, T.S., Iversen, O.E., Meri, S., Ascitic complement system in ovarian cancer (2005) British journal of cancer, 92, pp. 895-905Kim, D.Y., Martin, C.B., Lee, S.N., Martin, B.K., Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle (2005) Cancer immunology, immunotherapy: CII, 54, pp. 1026-1037Gollapalli, K., Ray, S., Srivastava, R., Renu, D., Singh, P., Dhali, S., Bajpai Dikshit, J., Srivastava, S., Investigation of serum proteome alterations in human glioblastoma multiforme (2012) Proteomics, 12, pp. 2378-2390Rutkowski, M.J., Sughrue, M.E., Kane, A.J., Ahn, B.J., Fang, S., Parsa, A.T., The complement cascade as a mediator of tissue growth and regeneration (2010) Inflammation research: official journal of the European Histamine Research Society, 59, pp. 897-905. , [et al]Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K., Koutoulaki, A., Gerard, C., Coukos, G., Lambris, J.D., Modulation of the antitumor immune response by complement (2008) Nature immunology, 9, pp. 1225-1235Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation (2011) Cell, 144, pp. 646-674Paiva, J.G., Florian-Cruz, L., Pedrini, H., Telles, G.P., Minghim, R., Improved similarity trees and their application to visual data classification (2011) IEEE transactions on visualization and computer graphics, 17, pp. 2459-2468Rousseeuw, P.J., Silhouettes: A graphical aid to the interpretation and validation of cluster analysis (1987) Journal of Computational and Applied Mathematics, 20, pp. 53-65Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G., Diagnosis of multiple cancer types by shrunken centroids of gene expression (2002) Proceedings of the National Academy of Sciences of the United States of America, 99, pp. 6567-6572Guyon, I.W., Barnhill, J., Vapnik, S., Gene Selection for Cancer Classification using Support Vector Machines (2002) Machine learning, 46, pp. 389-422Kuhn, M., Building Predictive Models in R Using the caret Package (2008) Journal of Statistical Software, 26, pp. 1-26Smit, S., Hoefsloot, H.C., Smilde, A.K., Statistical data processing in clinical proteomics (2008) Journal of chromatography B, Analytical technologies in the biomedical and life sciences, 866, pp. 77-88Carazzolle, M.F., de Carvalho, L.M., Slepicka, H.H., Vidal, R.O., Pereira, G.A., Kobarg, J., Meirelles, G.V., IIS-Integrated Interactome System: a web-based platform for the annotation, analysis and visualization of protein-metabolite-genedrug interactions by integrating a variety of data sources and tools (2014) PloS one, 9Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Yamanishi, Y., KEGG for linking genomes to life and the environment (2008) Nucleic acids research, 36, pp. D480-D484Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L., Ideker, T., Cytoscape 2, new features for data integration and network visualization (2011) Bioinformatics, 27, pp. 431-432Ponten, F., Schwenk, J.M., Asplund, A., Edqvist, P.H., The Human Protein Atlas as a proteomic resource for biomarker discovery (2011) Journal of internal medicine, 270, pp. 428-44

Integrative analysis to select cancer candidate biomarkers to targeted validation

FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOTargeted proteomics has flourished as the method of choice for prospecting for and validating potential candidate biomarkers in many diseases. However, challenges still remain due to the lack of standardized routines that can prioritize a limited number of proteins to be further validated in human samples. To help researchers identify candidate biomarkers that best characterize their samples under study, a well-designed integrative analysis pipeline, comprising MS-based discovery, feature selection methods, clustering techniques, bioinformatic analyses and targeted approaches was performed using discovery-based proteomic data from the secretomes of three classes of human cell lines (carcinoma, melanoma and non-cancerous). Three feature selection algorithms, namely, Beta-binomial, Nearest Shrunken Centroids (NSC), and Support Vector Machine-Recursive Features Elimination (SVM-RFE), indicated a panel of 137 candidate biomarkers for carcinoma and 271 for melanoma, which were differentially abundant between the tumor classes. We further tested the strength of the pipeline in selecting candidate biomarkers by immunoblotting, human tissue microarrays, label-free targeted MS and functional experiments. In conclusion, the proposed integrative analysis was able to pre-qualify and prioritize candidate biomarkers from discovery-based proteomics to targeted MS.Targeted proteomics has flourished as the method of choice for prospecting for and validating potential candidate biomarkers in many diseases. However, challenges still remain due to the lack of standardized routines that can prioritize a limited number of proteins to be further validated in human samples. To help researchers identify candidate biomarkers that best characterize their samples under study, a well-designed integrative analysis pipeline, comprising MS-based discovery, feature selection methods, clustering techniques, bioinformatic analyses and targeted approaches was performed using discovery-based proteomic data from the secretomes of three classes of human cell lines (carcinoma, melanoma and non-cancerous). Three feature selection algorithms, namely, Beta-binomial, Nearest Shrunken Centroids (NSC), and Support Vector Machine-Recursive Features Elimination (SVM-RFE), indicated a panel of 137 candidate biomarkers for carcinoma and 271 for melanoma, which were differentially abundant between the tumor classes. We further tested the strength of the pipeline in selecting candidate biomarkers by immunoblotting, human tissue microarrays, label-free targeted MS and functional experiments. In conclusion, the proposed integrative analysis was able to pre-qualify and prioritize candidate biomarkers from discovery-based proteomics to targeted MS6414363543652FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOCNPQ - CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO2009/54067-3; 2010/19278-0; 2011/22421-2; 2009/53839-2470567/2009-0; 470549/2011-4; 301702/2011-0; 470268/2013-

The metaRbolomics Toolbox in Bioconductor and beyond

Metabolomics aims to measure and characterise the complex composition of metabolites in a biological system. Metabolomics studies involve sophisticated analytical techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy, and generate large amounts of high-dimensional and complex experimental data. Open source processing and analysis tools are of major interest in light of innovative, open and reproducible science. The scientific community has developed a wide range of open source software, providing freely available advanced processing and analysis approaches. The programming and statistics environment R has emerged as one of the most popular environments to process and analyse Metabolomics datasets. A major benefit of such an environment is the possibility of connecting different tools into more complex workflows. Combining reusable data processing R scripts with the experimental data thus allows for open, reproducible research. This review provides an extensive overview of existing packages in R for different steps in a typical computational metabolomics workflow, including data processing, biostatistics, metabolite annotation and identification, and biochemical network and pathway analysis. Multifunctional workflows, possible user interfaces and integration into workflow management systems are also reviewed. In total, this review summarises more than two hundred metabolomics specific packages primarily available on CRAN, Bioconductor and GitHub

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such therapies will require biomarker panels to identify early AD pathology, classify disease stage, monitor pathological progression, and predict cognitive decline. To discover such biomarkers, we measured AD-associated changes in the cerebrospinal fluid (CSF) proteome.CSF samples from individuals with mild AD (Clinical Dementia Rating [CDR] 1) (n = 24) and cognitively normal controls (CDR 0) (n = 24) were subjected to two-dimensional difference-in-gel electrophoresis. Within 119 differentially-abundant gel features, mass spectrometry (LC-MS/MS) identified 47 proteins. For validation, eleven proteins were re-evaluated by enzyme-linked immunosorbent assays (ELISA). Six of these assays (NrCAM, YKL-40, chromogranin A, carnosinase I, transthyretin, cystatin C) distinguished CDR 1 and CDR 0 groups and were subsequently applied (with tau, p-tau181 and Aβ42 ELISAs) to a larger independent cohort (n = 292) that included individuals with very mild dementia (CDR 0.5). Receiver-operating characteristic curve analyses using stepwise logistic regression yielded optimal biomarker combinations to distinguish CDR 0 from CDR>0 (tau, YKL-40, NrCAM) and CDR 1 from CDR<1 (tau, chromogranin A, carnosinase I) with areas under the curve of 0.90 (0.85-0.94 95% confidence interval [CI]) and 0.88 (0.81-0.94 CI), respectively.Four novel CSF biomarkers for AD (NrCAM, YKL-40, chromogranin A, carnosinase I) can improve the diagnostic accuracy of Aβ42 and tau. Together, these six markers describe six clinicopathological stages from cognitive normalcy to mild dementia, including stages defined by increased risk of cognitive decline. Such a panel might improve clinical trial efficiency by guiding subject enrollment and monitoring disease progression. Further studies will be required to validate this panel and evaluate its potential for distinguishing AD from other dementing conditions

Proteomics: Clinical and research applications in respiratory diseases

The proteome is the study of the protein content of a definable component of an organism in biology. However, the tissue‐specific expression of proteins and the varied post‐translational modifications, splice variants and protein–protein complexes that may form, make the study of protein a challenging yet vital tool in answering many of the unanswered questions in medicine and biology to date. Indeed, the spatial, temporal and functional composition of proteins in the human body has proven difficult to elucidate for many years. Given the effect of microRNA and epigenetic regulation on silencing and enhancing gene transcription, the study of protein arguably provides more accurate information on homeostasis and perturbation in health and disease. There have been significant advances in the field of proteomics in recent years, with new technologies and platforms available to the research community. In this review, we briefly discuss some of these new technologies and developments in the context of respiratory disease. We also discuss the types of data science approaches to analyses and interpretation of the large volumes of data generated in proteomic studies. We discuss the application of these technologies with regard to respiratory disease and highlight the potential for proteomics in generating major advances in the understanding of respiratory pathophysiology into the future.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146450/1/resp13383_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146450/2/resp13383.pd

Pathway-Based Multi-Omics Data Integration for Breast Cancer Diagnosis and Prognosis.

Ph.D. Thesis. University of Hawaiʻi at Mānoa 2017